everyone's entitled to my opinion
 Most recent novel |
Visit the MESSAGE BOARDS Where everyone knows how sleep-deprived you are |
 Short crime musical with armed thugs in drag |
 Short screen opera about God, with funny parts |
Read/Post Comments (1)
Father of twins and novelist/filmmaker/musician
in New York on the
Upper Upper Upper Upper
Upper West Side.
People complain about musicals.
Nobody just stops in the street
I say you know the wrong people.
They say:
and breaks into song.
Antegren trials
Today Biogen/Elan announced that "the Phase III induction trial of ANTEGREN® (natalizumab) did not meet the primary endpoint" for Crohn's Disease.
Biogen stocks have fallen 6% today. If I understand this correctly, Phase III is the big, final drug trial with lots of people--the last test prior to FDA approval. It comes after a successful Phase II, which uses a much smaller sampling of people.
However, the results aren't in yet for the Antegren trials for multiple sclerosis. I hear through various grapevines that the Phase III results are mirroring the Phase II results--an 85-95% decrease in new MS lesions. This is from a once-a-month IV treatment. The stuff I'm on now, Rebif, is a three-times-a-week subcutaneous self-injection, and the most I can hope for is a 30% reduction in new lesions. (And I have to get blood tests every three months to find out whether it's hurting my liver, since it's an interferon.)
So who knows? This may be a good day to buy Biogen stock.
In other news, Montel Williams is annoying people with MS again: Newsgroup thread
Biogen stocks have fallen 6% today. If I understand this correctly, Phase III is the big, final drug trial with lots of people--the last test prior to FDA approval. It comes after a successful Phase II, which uses a much smaller sampling of people.
However, the results aren't in yet for the Antegren trials for multiple sclerosis. I hear through various grapevines that the Phase III results are mirroring the Phase II results--an 85-95% decrease in new MS lesions. This is from a once-a-month IV treatment. The stuff I'm on now, Rebif, is a three-times-a-week subcutaneous self-injection, and the most I can hope for is a 30% reduction in new lesions. (And I have to get blood tests every three months to find out whether it's hurting my liver, since it's an interferon.)
So who knows? This may be a good day to buy Biogen stock.
In other news, Montel Williams is annoying people with MS again: Newsgroup thread
Read/Post Comments (1)
Previous Entry :: Next Entry
Back to Top
